Form 4: Tango Therapeutics Director Reports New Equity Compensation Awards

Tango Therapeutics, Inc. Director Lesley Ann Calhoun reported the acquisition of 6,250 restricted stock units and 37,500 stock options on June 5, 2025, as part of her compensation.

Summary

• Director Lesley Ann Calhoun of Tango Therapeutics, Inc. reported new equity awards on June 5, 2025, as detailed in a Form 4 filing.
• She acquired 6,250 shares of Common Stock in the form of Restricted Stock Units (RSUs) at an acquisition price of $0.
• These RSUs are scheduled to vest in their entirety on the earlier of June 5, 2026, or the date of the next annual meeting of stockholders, contingent upon her continuous service with the Issuer.
• Additionally, Ms. Calhoun acquired 37,500 stock options with an exercise price of $3.51 per share and an expiration date of June 5, 2035.
• These stock options will vest in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, also subject to her continuous service.
• Following these reported transactions, Ms. Calhoun beneficially owns 12,500 shares of Common Stock and 37,500 stock options.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation for a director, which is generally a neutral to slightly positive event as it aligns interests. There are no negative operational or financial disclosures.

Positives

• The acquisition of restricted stock units and stock options aligns the director's interests with long-term shareholder value, as these awards typically vest over time and are tied to continued service and potential stock price appreciation.
• The awards represent a component of director compensation, indicating ongoing commitment and incentivization for leadership within Tango Therapeutics.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it primarily reports compensation-related equity awards.

Risks

• The ultimate value of the acquired restricted stock units and stock options is subject to the future performance and market price fluctuations of Tango Therapeutics' common stock.
• Vesting of both the RSUs and stock options is contingent upon the reporting person's continuous service with the Issuer, meaning forfeiture could occur if service ceases before the vesting conditions are met.

Future Outlook

This Form 4 primarily reports past equity awards and their future vesting schedules, which are contingent on continued service. It does not provide a broader future outlook for the company's operations or financial performance.

Industry Context

This filing reflects standard equity compensation practices for directors in the biotechnology or pharmaceutical industry, where long-term incentives like RSUs and stock options are common to align leadership interests with company growth and shareholder returns. It does not provide specific industry-wide trends or competitive analysis.

Stakeholder Impact

• Shareholders: The issuance of RSUs and stock options can lead to minor dilution over time as they vest and are exercised, but also serves to align director incentives with shareholder value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The Restricted Stock Units are scheduled to vest on the earlier of June 5, 2026, or the date of the next annual meeting of stockholders.
• The stock options will begin vesting on July 5, 2025, in 12 equal monthly installments over one year.

Key Dates

Keywords

Tango Therapeutics, TNGX, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, stock options, equity compensation, director compensation, beneficial ownership